014sek
-5,2 %
Date:2024-05-21Time:17:29:49Latest report:Q1-2024List:First NorthTicker:CYXO
Market Cap:30 msekEnterprise Value:18 msekNet Sales:- msekEarnings:-22,7 msekEmployees:0ISIN:SE0007815428

Ratios

10-year key figure history for Cyxone turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Cyxone with index and moving average MA50 and MA200.

Stockprice:0,14
MA50:0,09
MA200:0,18
Price/MA200:-21,8 %
RSI (14):74,6
Price/MA50:45,1 %

Description

Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.

Biotechnology